ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Einhorn, L. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Einhorn, L. H.

Ann Thorac Surg 1988;46:362-365
© 1988 The Society of Thoracic Surgeons

Articles

Neoadjuvant Therapy of Stage III Non-Small Cell Lung Cancer

Lawrence H. Einhorn, M.D.*

From the Department of Medicine, Indiana University Medical Center, Indianapolis, IN

* Address reprint requests to Dr. Einhorn, Department of Medicine, Hematology/Oncology, Indiana University Medical Center, 926 West Michigan, UH A109, Indianapolis, IN 46223.

During the past several years, there has been a resurgence of interest in preoperative or postoperative chemotherapy in patients with Stage III lung cancer.

The staging system for lung cancer has recently been modified, and at the present time Stage III disease is now subdivided into Stage III-A (potentially surgically resectable for cure) and Stage III-B (unresectable). This article will review five recently completed studies utilizing neo-adjuvant therapy in various types of Stage III lung cancer. The thoracic surgeon is faced with the dilemma of reviewing this literature and trying to make a conclusion as to what is appropriate therapy for Stage III disease. Unquestionably, neoadjuvant therapy appears to increase the re-sectability rate in Stage III-A disease and can make some Stage III-B patients anatomically resectable. It is hoped that future well-designed phase III studies can be accomplished in Stages III-A and III-B disease so that we can determine whether neoadjuvant chemotherapy is or is not beneficial for these patients.




This article has been cited by other articles:


Home page
 Eur J Cardiothorac SurgHome page
H. Wada, R. Miyahara, F. Tanaka, S. Hitomi, and West Japan Study Group for lung cancer surgery (WJ
Postoperative adjuvant chemotherapy with PVM (Cisplatin+Vindesine+Mitomycin C) and UFT (Uracil+Tegaful) in resected stage I-II NSCLC (non-small cell lung cancer): a randomized clinical trial
Eur J Cardiothorac Surg, April 1, 1999; 15(4): 438 - 443.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
L. H. Einhorn
Neoadjuvant and Adjuvant Trials in Non-Small Cell Lung Cancer
Ann. Thorac. Surg., January 1, 1998; 65(1): 208 - 211.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
J. D. Miller, L. A. Gorenstein, and G. A. Patterson
Staging: The key to rational management of lung cancer
Ann. Thorac. Surg., January 1, 1992; 53(1): 170 - 178.
[Abstract] [PDF]

Home page
 JAMAHome page
W. S. Pierce
Cardiothoracic Surgery
JAMA, May 19, 1989; 261(19): 2827 - 2829.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1988 by The Society of Thoracic Surgeons.